Xifaxan's Expanded Indication Comes With Additional Safety, Efficacy Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
After drug gains approval to prevent recurrence of hepatic encephalopathy, Salix plans studies in patients with end-stage liver disease and in patients not taking lactulose.
You may also be interested in...
Panel To Help Define Target Population For Xifaxan Reuse In IBS-D
FDA’s Gastrointestinal Drugs Advisory Committee Nov. 16 will review a trial design for evaluating the safety and efficacy of retreatment for the chronic condition with Silax’s antibiotic Xifaxan.
GI Drugs Cmte. To Weigh Retreatment Study Design For Salix's Xifaxan In Irritable Bowel
On Nov. 16, FDA's outside advisors will discuss the design of clinical trials to evaluate the safety, efficacy and durability of response with repeat treatment cycles of rifaximin for diarrhea-predominant IBS.
GI Drugs Cmte. To Weigh Retreatment Study Design For Salix's Xifaxan In Irritable Bowel
On Nov. 16, FDA's outside advisors will discuss the design of clinical trials to evaluate the safety, efficacy and durability of response with repeat treatment cycles of rifaximin for diarrhea-predominant IBS.